🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Meet Dr. Nawaz Khan, the new Head of Research at BioVersys! Specializing in antimicrobial drug development, he’s set to boost our R&D and collaborations. Welcome aboard, Nawaz! 🚀 #newhire #BioVersys

Our CEO will represent BEAM Alliance at the World Health Summit in Berlin today. Join experts to discuss sustainable new antibiotics. Hosted by DNAMR.de. 📅 Oct. 16, 2023, 🕓CEST: 04:00 PM 🖥️ Join here:lnkd.in/dnzE_r2q Stay tuned! #BEAMAlliance #Antibiotics

BioVersys is excited to be part of #BIOEurope in Munich, taking place from November 6 to 8, 2023. We invite you to request a partnering meeting with us at the event. Let's connect and explore opportunities together! Learn more: lnkd.in/dnuNZ2D

🌟Major Step for BioVersys! Thrilled to introduce Hernan Levett as our new CFO. His 30-year track record will fortify our financial strategy as we approach vital milestones.👉See attached press release for details. bioversys.com/bioversys-appo… 🔗#BioVersysTalks #NewCFO

🌍 Join BioVersys in the fight against Antimicrobial Resistance! 🤝 Raise awareness during World AMR Awareness Week (18-24 Nov). 🎗️ Share to amplify the message and contribute to the global health cause. 💙 #AMRAwareness #OneHealth #SpreadTheWord #StopAMR #BioVersys

🎉 Big news! @BioVersys has received FDA orphan-drug designation for our anti-TB drug candidate alpibectir, & ethionamide combo. A game-changer in fighting drug-resistant TB. 🌍  Read more:  bioversys.com/bioversys-rece…

🚨 Exciting collaboration alert! #BioVersys & #HelmholtzCentre join forces against AMR! 🔬 🤝 Combining our R&D expertise to innovate and deliver new AMR solutions.💡 Supported by DZIF, we're tackling life-threatening infections together! Full PR 🔗: lnkd.in/diGZTtz3

Meet Jonathan Butcher at the European Life Sciences CEO Forum, Feb 28th-29th, 2024, Hilton Zurich, to dive into innovative AMR solutions! 🚀 Explore investment/collab opportunities with us. Book your slot via one-to-one or [email protected]. #AMRInnovation #LifeSciences #BioVersys

🚀 BioVersys & GSK achieve exciting milestone in TB treatment with the completion of the IMI2-funded TRIC-TB program & the introduction of alpibectir, a Phase 2-ready candidate. A giant leap towards overcoming TB! 🌍💊 #BioVersys #HealthcareInnovation bioversys.com/bioversys-and-…

🌐 Our new patient section is live, spotlighting our battle against AMR and our patient-centric solutions. Dive into innovation and join our mission to safeguard the future of the world’s healthcare. ➡️Check it out here:bioversys.com/patients/. #PatientCare #BioVersys

BioVersys announces expansion of collaboration with GSK and extension of Series C (CHF 12.3m) to CHF 44.9m. BioVersys strives to bring urgently needed medicines to patients, with strong partners, GSK, & loyal investors, we're firmly on track.🌍💊 Full PR: bioversys.com/?p=5300

CHF 12.3 million to boost novel drugs against tuberculosis: TOP 100 Swiss scale-up BioVersys secures its Series C and expands collaboration with GSK. Congrats to the world-class team led by biotech pioneers Marc Gitzinger, Sergio Lociuro, and Glenn Dale! venturekick.ch/BioVersys-stre…

🎉 We're excited to announce that BioVersys has been awarded with non-dilutive funding via our CDP programme to advance the pipeline of preclinical assets for CF lung infections. Read the press release ow.ly/rTUe50S8cEx Medicines Discovery Catapult | Cystic Fibrosis Trust | LifeArc

🤝 We are excited to collaborate with LifeArc, Medicines Discovery Catapult and Cystic Fibrosis Trust to expedite BioVersys’ NTM program to address serious infections in people living with CF.  💊 See PR with details: lnkd.in/gRiVDdux

#PassThePasteurAct

BioVersys announces strategic investment from GIBF2 and launch of BV100 clinical program in China. · GIBF2 to invest US$ 6m in BioVersys · BV100 Phase 1 study in China expected to start in 1H 2025 Press release: bioversys.com/5454-2/ #AMR #investment #China #Innovation

📡 Exciting times as BioVersys announces last patient, last visit in the Phase 2 clinical trial with BV100 showing positive first signs of efficacy for #VABP #CRAB. 🎯🌍 🏥 🚀 Read the full press release here: bioversys.com/?p=5490 #SavingLivesinResistantTimes #AMR #Innovation

BioVersys announces joining the IMI AMR ACCELERATOR EU-funded programme @RespiriNTM, access to up to €2 m in non-dilutive funding for our broad-spectrum NTM project. Read the full press release here: bioversys.com/?p=5519 #SavingLivesinResistantTimes #AMR #investment #Innovation

Click lifescievents.com/event/bioversy… for an informative KOL event; May 7, 2025, 8:30 AM ET / 2:30PM CEST. Featuring Professor David Paterson & Dr. Andrew Shorr, MD, discussing the unmet need & current treatment landscape for carbapenem resistant Acinetobacter baumannii pneumonia. #AMR

📡 BioVersys and SHIONOGI, enter into Global Research Collaboration for broad-spectrum NTM clinical candidates. Read more here: linkedin.com/feed/update/ur…